TY - JOUR
T1 - Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance
AU - Mazouji, Omayma
AU - Ouhajjou, Abdelhak
AU - Incitti, Roberto
AU - Mansour, Hicham
N1 - KAUST Repository Item: Exported on 2021-06-28
Acknowledgements: We thank Majda Llbiyi undergraduate student for drawing Figure 1. Funding. The research funding of the university has supported this work. Publication fees supported by the Cancer Research Institute IRC, Kingdom of Morocco.
PY - 2021/5/24
Y1 - 2021/5/24
N2 - Colorectal cancer (CRC) is one of the most common cancers worldwide, being the third most diagnosed in the world and the second deadliest. Solid biopsy provides an essential guide for the clinical management of patients with colorectal cancer; however, this method presents several limitations, in particular invasiveness, and cannot be used repeatedly. Recently, clinical research directed toward the use of liquid biopsy, as an alternative tool to solid biopsy, showed significant promise in several CRC clinical applications, as (1) detect CRC patients at early stage, (2) make treatment decision, (3) monitor treatment response, (4) predict relapses and metastases, (5) unravel tumor heterogeneity, and (6) detect minimal residual disease. The purpose of this short review is to describe the concept, the characteristics, the genetic components, and the technologies used in liquid biopsy in the context of the management of colorectal cancer, and finally we reviewed gene alterations, recently described in the literature, as promising potential biomarkers that may be specifically used in liquid biopsy tests.
AB - Colorectal cancer (CRC) is one of the most common cancers worldwide, being the third most diagnosed in the world and the second deadliest. Solid biopsy provides an essential guide for the clinical management of patients with colorectal cancer; however, this method presents several limitations, in particular invasiveness, and cannot be used repeatedly. Recently, clinical research directed toward the use of liquid biopsy, as an alternative tool to solid biopsy, showed significant promise in several CRC clinical applications, as (1) detect CRC patients at early stage, (2) make treatment decision, (3) monitor treatment response, (4) predict relapses and metastases, (5) unravel tumor heterogeneity, and (6) detect minimal residual disease. The purpose of this short review is to describe the concept, the characteristics, the genetic components, and the technologies used in liquid biopsy in the context of the management of colorectal cancer, and finally we reviewed gene alterations, recently described in the literature, as promising potential biomarkers that may be specifically used in liquid biopsy tests.
UR - http://hdl.handle.net/10754/669781
UR - https://www.frontiersin.org/articles/10.3389/fcell.2021.660924/full
UR - http://www.scopus.com/inward/record.url?scp=85108095574&partnerID=8YFLogxK
U2 - 10.3389/fcell.2021.660924
DO - 10.3389/fcell.2021.660924
M3 - Article
C2 - 34150757
SN - 2296-634X
VL - 9
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
ER -
